COCP - Cocrystal Pharma Inc. (COCP) - Cocrystal Announces CC-42334 To Start Clinical Studies in Influenza

The Product Pipeline Advances Cocrystal announced that it has completed studies to file an IND for CC-42344, its PB2 inhibitor for the treatment of seasonal and pandemic influenza A. The first Phase 1 study is planned for 3Q21.CC-42334 Has A Unique Mechanism Of Action CC-42334 was developed using Cocrystal’s proprietary anti-viral technology, targeting an enzyme early in the process of producing the next viral generation. This differs from other anti-influenza approaches that are based on stimulating an immune response or blocking viral surface proteins.CC-42344 Blocks An Enzyme Needed By The Influenza Virus To Reproduce CC-42344 binds to PB2, an area of the viral polymerase complex that is needed for viral replication. Blocking this protein stops the first step in viral replication, reducing the viral load and then eliminating the infection.A CRO Has Been Selected, Clinical Trials Expected To Begin Soon Cocrystal has selected a clinical research organization (CRO) to conduct the trial and plans to initiate a Phase 1 study in Australia during 3Q21. This location allows favorable regulatory pathways and financial incentives from the Australian government for clinical trials conducted in the country.Conclusion The start of Phase 1 for CC-42344 is one of the milestones we had expected to drive the company. We are reiterating our Outperform rating and price target of $5. Read More >>